IADVL
Indexed with PubMed and Science Citation Index (E) 
 
Users online: 3817 
     Home | Feedback | Login 
About Current Issue Archive Ahead of print Search Instructions Online Submission Subscribe What's New Contact  
  Navigate here 
  Search
 
  
 Resource links
   Similar in PUBMED
    Search Pubmed for
    Search in Google Scholar for
   Article in PDF (304 KB)
   Citation Manager
   Access Statistics
   Reader Comments
   Email Alert *
   Add to My List *
* Registration required (free)  

 
  In this article
   References

 Article Access Statistics
    Viewed1580    
    Printed13    
    Emailed0    
    PDF Downloaded100    
    Comments [Add]    

Recommend this journal

 


 
 Table of Contents    
LETTER TO THE EDITOR - LETTERS IN RESPONSE TO PUBLISHED ARTICLES
Year : 2016  |  Volume : 82  |  Issue : 6  |  Page : 684-686

Author reply: Biologics or biosimilars: What is the difference?


Department of Dermatology and Venereology, All India Institute of Medical Sciences, New Delhi, India

Date of Web Publication7-Oct-2016

Correspondence Address:
Dr. Vinod Kumar Sharma
Department of Dermatology and Venereology, All India Institute of Medical Sciences, New Delhi
India
Login to access the Email id

Source of Support: None, Conflict of Interest: None


DOI: 10.4103/0378-6323.191539

Rights and Permissions



How to cite this article:
Sharma VK, Bhari N, Gupta S, Sahni K, Khanna N, Ramam M, Sethuraman G. Author reply: Biologics or biosimilars: What is the difference?. Indian J Dermatol Venereol Leprol 2016;82:684-6

How to cite this URL:
Sharma VK, Bhari N, Gupta S, Sahni K, Khanna N, Ramam M, Sethuraman G. Author reply: Biologics or biosimilars: What is the difference?. Indian J Dermatol Venereol Leprol [serial online] 2016 [cited 2019 Oct 16];82:684-6. Available from: http://www.ijdvl.com/text.asp?2016/82/6/684/191539


Sir,

We thank the authors for their interest in the article “Clinical efficacy of rituximab in the treatment of pemphigus: A retrospective study” and their valuable comments.[1] In their letter, a query regarding the brand of rituximab (biologic/biosimilar) used in our study has been submitted. We have deliberately not mentioned the name of rituximab company/brand used as our study was not supported by any pharmaceutical company and we did not want to inadvertently promote a brand. We used a biosimilar of rituximab (Reditux, Dr. Reddy's Laboratories) in all of our patients. We chose above brand as it was easily available and low priced. Recently, it has been found to have the same efficacy in depleting the B-cells, when compared to the original molecule.[2] We agree that biosimilars can have variable efficacy in different brands and sometimes in different batches of the same brand; hence, it is appropriate to mention the brand used in a study.

Regarding the observation of discordance between the text and table, whereas mentioning the past treatment of dexamethasone/dexamethasone-cyclophosphamide pulse therapy was concerned, we would like to clarify that the past treatment mentioned in the table refers to the treatment given in our institute. Ten out of 21 recalcitrant patients received dexamethasone/dexamethasone-cyclophosphamide pulse/cyclophosphamide pulse therapy from our institute while five patients (patient no. 3, 9, 14, 22, 24) received corticosteroid pulse treatment outside. Other six recalcitrant patients only received oral immunosuppressive therapy; however, as one of these patients received treatment outside our institute, the details were not available in the proforma.

Regarding the use of long-term maintenance immunosuppressive therapy after dexamethasone/dexamethasone-cyclophosphamide pulse, as per the protocol described by Pasricha et al., an adjuvant (cyclophosphamide 50 mg oral daily/azathioprine 50 mg twice daily orally) was used along with dexamethasone/dexamethasone-cyclophosphamide pulse/cyclophosphamide pulse therapy in eight patients though details were not available for other patients.[3]

The query regarding the benefit of rituximab on dexamethasone-cyclophosphamide pulse in recalcitrant pemphigus was not addressed in this study. We have observed that the number of hospital and day care visits is far less with rituximab as only two injections require hospitalization or day care visit and rest of the treatment regimen can be managed on outpatient basis. However, the paradoxical exacerbation after rituximab may require an additional inpatient care. The overall corticosteroid intake is significantly reduced with rituximab regimen compared to corticosteroid pulse therapy (mean cumulative dose = 3535.64 mg in our study). In our study, 21 patients were recalcitrant and we were able to achieve complete remission in 19 patients at 4.34 months. The main achievement of dexamethasone/dexamethasone-cyclophosphamide pulse therapy is the long-term remission after stopping therapy though it is too early to compare rituximab with dexamethasone-cyclophosphamide pulse therapy.[4] We have also observed that relapse rate after a single cycle of dexamethasone-cyclophosphamide pulse and rituximab is comparable (21% and 16%, respectively).[1],[5] In our study, we have used only one cycle of rituximab 1000 mg, at a 2-week interval; however, in future, we propose to use an additional cycle of rituximab if the patient at 6 months is not free of lesions or still needs prednisolone. There is an urgent need to agree on a rituximab regimen so that data from different studies being carried out in India can be compared.

Financial support and sponsorship

Nil.

Conflicts of interest

There are no conflicts of interest.

 
  References Top

1.
Sharma VK, Bhari N, Gupta S, Sahni K, Khanna N, Ramam M, et al. Clinical efficacy of rituximab in the treatment of pemphigus: A retrospective study. Indian J Dermatol Venereol Leprol 2016;82:389-94.  Back to cited text no. 1
[PUBMED]  Medknow Journal  
2.
Gota V, Karanam A, Rath S, Yadav A, Tembhare P, Subramanian P, et al. Population pharmacokinetics of Reditux™, a biosimilar rituximab, in diffuse large B-cell lymphoma. Cancer Chemother Pharmacol 2016;78:353-9.  Back to cited text no. 2
[PUBMED]    
3.
Pasricha JS. Pulse therapy as a cure for autoimmune diseases. Indian J Dermatol Venereol Leprol 2003;69:323-8.  Back to cited text no. 3
[PUBMED]  Medknow Journal  
4.
Pasricha JS, Khaitan BK, Raman RS, Chandra M. Dexamethasone-cyclophosphamide pulse therapy for pemphigus. Int J Dermatol 1995;34:875-82.  Back to cited text no. 4
[PUBMED]    
5.
Pasricha JS, editor. AIIMS experience. In: Pulse Therapy in Pemphigus and Other Diseases. 3rd ed. New Delhi: Mehta Publishers; 2006. p. 67-71.  Back to cited text no. 5
    




 

Top
Print this article  Email this article

    

Online since 15th March '04
Published by Wolters Kluwer - Medknow